Tag: restricted stock

BAYONNE, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), today announced that, as previously reported on its Form 8-K filed on June 1, 2026, effective as of the close of trading on June 5, 2026, the Company granted 709,220 shares of restricted common stock, in accordance with Nasdaq Listing Rule 5635(c)(4), to Thomas M. O’Brien as an inducement material to Mr. O’Brien entering into an employment agreement with the Company and commencing employment as its Chief Executive Officer and President. Twenty percent of the shares of restricted stock will vest on each of December 31, 2026, December 31, 2027, December 31, 2028, December 31, 2029 and December 31, 2030, subject to Mr. O’Brien’s continued service with the Bank through each such vesting date, except that in certain circumstances described in the award, the restricted stock will vest in full.

BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,360 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.

CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.